Notable research news last week included US biopharma Avidity Biosciences announcing a positive update on its muscular ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

Fintel reports that on June 11, 2025, Raymond James initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Strong ...

Worldwide Healthcare Trust PLC - Annual Financial Report PR Newswire LONDON, United Kingdom, June 11 10 June 2025Worldwide Healthcare Trust PLC(the "Company") Annual Financial ...

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.42, along with a high estimate of $75.00 and a low estimate of $54.00. Surpassing the ...

Avidity Biosciences, based in San Diego, reported that it has confirmed with the FDA that the accelerated approval pathway is open for its investigational therapy, del-brax. This therapy is designed ...